An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 169-174

  Ternant, David ^a   Mulleman, Denis ^a   Degenne, Danielle ^a   Willot, Stéphanie ^a   Guillaumin, Jean Maurice ^a   Watier, Hervé ^a   Goupille, Philippe ^a   Paintaud, Gilles ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Enzyme linked immunosorbent assay; Infliximab; Pharmacokinetics

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 33748193708     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000189901.08684.4b     Document Type: Article

References (13)

1. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
2. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
4. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
5. Wolbink GJ, Voskuyl A, Lems W, et al. Relation between serum trough infliximab levels, pretreatment CRP levels and clinical response to infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64:704-707.
6. Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538-1543.
7. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
8. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol. 1998;9:527-534.
9. Chladek J, Martinkova J, Simkova M, et al. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998;53:1538-1543.
10. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 1995;85:668-674.
11. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15:463-473.
12. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-1453.
13. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985;260:2345-2354.